Top

Published in:

Open Access 01-12-2021 | Obesity | Research

The relationship between changes in serum myostatin and adiponectin levels in patients with obesity undergoing a weight loss program

Authors: Nana Takao, Satoshi Kurose, Takumi Miyauchi, Katsuko Onishi, Atsuko Tamanoi, Ryota Tsuyuguchi, Aya Fujii, Sawako Yoshiuchi, Kazuhisa Takahashi, Hiromi Tsutsumi, Yutaka Kimura

Published in: BMC Endocrine Disorders | Issue 1/2021

Abstract

Background

An effective strategy for weight loss in patients who are overweight or obese is to reduce body fat mass while maintaining skeletal muscle mass. Adiponectin and myostatin are affected through changes in body composition due to weight loss, and examining their dynamics may contribute to strategies for maintaining skeletal muscle mass through weight loss. We aimed to examine the relationships among myostatin, adiponectin, and body composition, depending on the extent of weight loss, in patients with obesity undergoing a weight loss program.

Methods

We examined 66 patients with obesity (age: 46.8 ± 14.0 years, body mass index: 34.3 [31.0–38.4] kg/m²) attending a hospital weight loss program. We categorized the patients into two groups, namely an L group (those with a weight reduction of < 5% from baseline) and an M group (those with a weight reduction of > 5% from baseline). All patients underwent blood tests and were assessed for body composition, insulin resistance, adipocytokine and myokine levels, exercise tolerance, and muscle strength at baseline and post-intervention.

Results

Serum myostatin and adiponectin levels increased post-intervention in both groups. Body weight and %fat decreased, and the rate of lean body mass (%LBM) increased in both groups. Exercise capacity and muscle strength improved in the M group only. Change in (⊿) myostatin correlated with ⊿%fat, ⊿%LBM, and ⊿adiponectin. ⊿adiponectin (β = − 0.262, p = 0.035) was an independent predictor of ⊿myostatin.

Conclusions

Myostatin and adiponectin might cross-talk and regulate changes in skeletal muscle and fat mass with or without successful weight loss. These findings indicate that evaluating serum myostatin and adiponectin levels in clinical practice could be used to predict the effects of weight loss and help prevent skeletal muscle mass loss.

Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33:673–89. https://doi.org/10.1007/s40273-014-0243-x.CrossRefPubMedPubMedCentral

Kurose S, Onishi K, Takao N, Miyauchi T, Takahashi K, Kimura Y. Association of serum adiponectin and myostatin levels with skeletal muscle in patients with obesity: a cross-sectional study. PLoS One. 2021;16:e0245678. https://doi.org/10.1371/journal.pone.0245678.

Delaigle AM, Senou M, Guiot Y, Many M-C, Brichard SM. Induction of adiponectin in skeletal muscle of type 2 diabetic mice: in vivo and in vitro studies. Diabetologia. 2006;49:1311–23. https://doi.org/10.1007/s00125-006-0210-y.CrossRefPubMed

Gamberi T, Modesti A, Magherini F, D'Souza DM, Hawke T, Fiaschi T. Activation of autophagy by globular adiponectin is required for muscle differentiation. Biochim Biophys Acta. 1863;2016:694–702. https://doi.org/10.1016/j.bbamcr.2016.01.016.CrossRef

Bucci L, Yani SL, Fabbri C, Bijlsma AY, Maier AB, Meskers CG, et al. Circulating levels of adipokines and IGF-1 are associated with skeletal muscle strength of young and old healthy subjects. Biogerontology. 2013;14:261–72. https://doi.org/10.1007/s10522-013-9428-5.CrossRefPubMed

Huang C, Tomata Y, Kakizaki M, Sugawara Y, Hozawa A, Momma H, et al. High circulating adiponectin levels predict decreased muscle strength among older adults aged 70 years and over: a prospective cohort study. Nutr Metab Cardiovasc Dis. 2015;25:594–601. https://doi.org/10.1016/j.numecd.2015.03.010.CrossRefPubMed

Allen DL, Hittel DS, McPherron AC. Expression and function of myostatin in obesity, diabetes, and exercise adaptation. Med Sci Sports Exerc. 2011;43:1828–35. https://doi.org/10.1249/MSS.0b013e3182178bb4.CrossRefPubMedPubMedCentral

Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, McPherron AC. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One. 2009;4:e4937. https://doi.org/10.1371/journal.pone.0004937.CrossRefPubMedPubMedCentral

Hittel DS, Axelson M, Sarna N, Shearer J, Huffman KM, Kraus WE. Myostatin decreases with aerobic exercise and associates with insulin resistance. Med Sci Sports Exerc. 2010;42:2023–9. https://doi.org/10.1249/MSS.0b013e3181e0b9a8.CrossRefPubMedPubMedCentral

10.

Summer SS, Brehm BJ, Benoit SC, D'Alessio DA. Adiponectin changes in relation to the macronutrient composition of a weight-loss diet. Obesity (Silver Spring). 2011;19:2198–204. https://doi.org/10.1038/oby.2011.60.CrossRef

11.

Ryan AS, Li G, Blumenthal JB, Ortmeyer HK. Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults. Obesity (Silver Spring). 2013;21:1350–6. https://doi.org/10.1002/oby.20216.CrossRef

12.

Tsioga MN, Oikonomou D, Vittas S, Kalscheuer H, Roeder E, Wintgens KF, et al. Plasma myostatin is only a weak predictor for weight maintenance in obese adults. Exp Clin Endocrinol Diabetes. 2015;123:466–72. https://doi.org/10.1055/s-0035-1559663.CrossRefPubMed

13.

Ma W, Huang T, Zheng Y, Wang M, Bray GA, Sacks FM, et al. Weight-loss diets, adiponectin, and changes in cardiometabolic risk in the 2-year POUNDS lost trial. J Clin Endocrinol Metab. 2016;101:2415–22. https://doi.org/10.1210/jc.2016-1207.CrossRefPubMedPubMedCentral

14.

Corbi G, Polito R, Monaco ML, Cacciatore F, Scioli M, Ferrara N, et al. Adiponectin expression and genotypes in Italian people with severe obesity undergone a hypocaloric diet and physical exercise program. Nutrients. 2019;11:2195. https://doi.org/10.3390/nu11092195.CrossRefPubMedCentral

15.

Japan Society for the Study of Obesity. Guidelines for the Management of Obesity Disease. Tokyo: life science co. Ltd. 2016;2016:57–70.

16.

Cefalu WT, Bray GA, Home PD, Garvey WT, Klein S, Pi-Sunyer FX, et al. Advances in the science, treatment, and prevention of the disease of obesity: Reflections from a diabetes care editors' expert forum. Diabetes Care. 2015;38:1567–82. https://doi.org/10.2337/dc15-1081.CrossRefPubMedPubMedCentral

17.

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140:e596–646.PubMedPubMedCentral

18.

Fukushima Y, Kurose S, Shinno H, Thu HC, Takao N, Tsutsumi H, et al. Importance of lean muscle maintenance to improve insulin resistance by body weight reduction in female patients with obesity. Diabetes Metab J. 2016;40:147–53. https://doi.org/10.4093/dmj.2016.40.2.147.CrossRefPubMedPubMedCentral

19.

Kurose S, Tsutsumi H, Yamanaka Y, Shinno H, Miyauchi T, Tamanoi A, et al. Improvement in endothelial function by lifestyle modification focused on exercise training is associated with insulin resistance in obese patients. Obes Res Clin Pract. 2014;8:e106–14. https://doi.org/10.1016/j.orcp.2012.10.005.

20.

Beaver WL, Wasserman K, Whipp BJ. A new method for detecting the anaerobic threshold by gas exchange. J Appl Physiol. 1986;60:2020–7. https://doi.org/10.1152/jappl.1986.60.6.2020.

21.

Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381–95. https://doi.org/10.1249/01.MSS.0000078924.61453.FB.

22.

RMDS C, DCL M, Corgosinho FC, Carvalho-Ferreira JP, Molin Netto BD, APG C, et al. Relationship between adiponectin and leptin on osteocalcin in obese adolescents during weight loss therapy. Arch Endocrinol Metab. 2018;62:275–84. https://doi.org/10.20945/2359-3997000000039.

23.

Sharma M, McFarlane C, Kambadur R, Kukreti H, Bonala S, Srinivasan S. Myostatin: expanding horizons. IUBMB Life. 2015;67:589–600. https://doi.org/10.1002/iub.1392.CrossRefPubMed

24.

Parida S, Siddharth S, Sharma D. Adiponectin, obesity, and cancer: clash of the bigwigs in health and disease. Int J Mol Sci. 2019;20:E2519. https://doi.org/10.3390/ijms20102519.CrossRefPubMed

25.

Li F, Li Y, Duan Y, Hu CA, Tang Y, Yin Y. Myokines and adipokines: involvement in the crosstalk between skeletal muscle and adipose tissue. Cytokine Growth Factor Rev. 2017;33:73–82. https://doi.org/10.1016/j.cytogfr.2016.10.003.CrossRefPubMed

26.

Liu XH, Pan JP, Bauman WA, Cardozo CP. AdipoRon prevents myostatin-induced upregulation of fatty acid synthesis and downregulation of insulin activity in a mouse hepatocyte line. Phys Rep. 2019;7:e14152. https://doi.org/10.14814/phy2.14152.CrossRef

27.

Feldman BJ, Streeper RS, Farese RV Jr, Yamamoto KR. Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects. Proc Natl Acad Sci U S A. 2006;103:15675–80. https://doi.org/10.1073/pnas.0607501103.CrossRefPubMedPubMedCentral

28.

Tanaka M, Masuda S, Yamakage H, Inoue T, Ohue-Kitano R, Yokota S, et al. Role of serum myostatin in the association between hyperinsulinemia and muscle atrophy in Japanese obese patients. Diabetes Res Clin Pract. 2018;142:195–202. https://doi.org/10.1016/j.diabres.2018.05.041.CrossRefPubMed

29.

Quirós Cognuck S, Reis WL, Silva M, Debarba LK, Mecawi AS, de Paula FJA, et al. Sex differences in body composition, metabolism-related hormones, and energy homeostasis during aging in Wistar rats. Phys Rep. 2020;8:e14597. https://doi.org/10.14814/phy2.14597.CrossRef

30.

Sharma N, Castorena CM, Cartee GD. Greater insulin sensitivity in calorie restricted rats occurs with unaltered circulating levels of several important myokines and cytokines. Nutr Metab (Lond). 2012;9:90. https://doi.org/10.1186/1743-7075-9-90.CrossRef

31.

Lyons JA, Haring JS, Biga PR. Myostatin expression, lymphocyte population, and potential cytokine production correlate with predisposition to high-fat diet induced obesity in mice. PLoS One. 2010;5:e12928. https://doi.org/10.1371/journal.pone.0012928.CrossRefPubMedPubMedCentral

32.

Ma W, Huang T, Heianza Y, Wang T, Sun D, Tong J, et al. Genetic variations of circulating adiponectin levels modulate changes in appetite in response to weight-loss diets. J Clin Endocrinol Metab. 2017;102:316–25. https://doi.org/10.1210/jc.2016-2909.CrossRefPubMed

33.

Han D-S, Chu-Su Y, Chiang C-K, Tseng F-Y, Tseng P-H, Chen C-L, et al. Serum myostatin is reduced in individuals with metabolic syndrome. PLoS One. 2014;9:e108230. https://doi.org/10.1371/journal.pone.0108230.CrossRefPubMedPubMedCentral

Title: The relationship between changes in serum myostatin and adiponectin levels in patients with obesity undergoing a weight loss program
Authors: Nana Takao
Satoshi Kurose
Takumi Miyauchi
Katsuko Onishi
Atsuko Tamanoi
Ryota Tsuyuguchi
Aya Fujii
Sawako Yoshiuchi
Kazuhisa Takahashi
Hiromi Tsutsumi
Yutaka Kimura
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Obesity
Obesity
Insulins
Insulins
Published in: BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-021-00808-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

The BAriatic surgery SUbstitution and nutrition (BASUN) population: a data-driven exploration of predictors for obesity

Apoplexy of Crooke cell tumour leading to the diagnosis of severe Cushing disease; a case report

Misleading localization by 18F-fluorocholine PET/CT in familial hypocalciuric hypercalcemia type-3: a case report

Outcomes of endoscopic transsphenoidal surgery for Cushing's disease

Lower normal free thyroxine is associated with a higher risk of metabolic syndrome: a retrospective cohort on Chinese population

Endogenous estrogen exposure and chronic kidney disease; a 15-year prospective cohort study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials